ONCY · Oncolytics Biotech Inc · Executive Compensation
$0.59
-0.01 (-1.64%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we expect that our existing cash resources, even when considered together with capital that may be raised under our equity distribution arrangements, are sufficient to fund near‑term operating milestones but are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our condensed consolidated financial statements included in this quarterly report. These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$87.13M
Shares
127.51M
Volume · Oct 6
139.57K
Avg daily vol (3M)
1.12M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Stephen Glover | director | Appointed | 2026-06-02 |
| John McAdory | Chief Operating Officer | Appointed | 2026-06-02 |